glp 1 agonist uses glp-1_analogs [TUSOM Benefits and Risks of GLP-1
Description
doi: 10.1186/s12974-018-1370-7 [DOI] [PMC free article] [PubMed] [Google Scholar] 126
Fitzgerald, K
In the SURMOUNT-1 trials, the tirzepatide group lost about 20.2% of baseline body weight in 72 weeks, while the semaglutide group lost about 13.7 %
A required part of this site couldnt load
doi: 10.1093/ejendo/lvac004 28 ChristensenMBLundACalannaSJrgensenNRHolstJJVilsbllTet al
Samms RJ, Kusminski CM
